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IN recognition sequencesIntegrase (IN) is the enzyme responsible for provirus integration of retroviruses into the host cell genome.
We used an Avian Sarcoma and Leukemia Viruses (ASLV) integration assay to investigate the way in which IN
integrates substrates mutated or devoid of one or both IN recognition sequences. We found that replacing U5
by non-viral sequences (U5del) or U3 by a mutated sequence (pseudoU3) resulted in two and three fold
reduction of two-ended integration (integration of the two ends from a donor DNA) respectively, but had a
slight effect on concerted integration (integration of both ends at the same site of target DNA). Further, IN
was still able to integrate the viral ends of the double mutant (pseudoU3/U5del) in a two-ended and
concerted integration reaction. However, efﬁciency and accuracy (i.e. ﬁdelity of size duplication and of end
cleavage) of integration were reduced.
© 2009 Elsevier Inc. All rights reserved.IntroductionIntegrase (IN) is the virally-encoded enzyme that catalyzes
integration of the reverse transcribed viral DNA into the host cell
DNA (Craigie et al., 1990; Katzman et al., 1989), an essential
prerequisite for retroviral replication (Brown, 1997). The integration
process occurs in three steps. In the ﬁrst (or 3′-processing) step, IN
cleaves the two terminal nucleotides at each 3′ end of the newly
synthesized viral DNA to generate a CA-3′ OH end, with a two-bases 5′
overhang. In the second step (strand transfer), the 3′ viral ends are
linked to the host DNA. In the ﬁnal step (gap ﬁlling), the overhanging
5′ dinucleotides of the viral DNA ends are removed and single-
stranded host DNA gaps are repaired, probably by cellular enzymes
(Smith and Daniel, 2006) generating a short duplication of the host
DNA sequence on both sides of the provirus. As a result of this process,
the provirus is characterized by deletion of the two terminal base
pairs, is ﬂanked by the canonical 5′-TG…CA-3′ viral termini and
exhibits duplication of a short cellular DNA sequence. The integrationll rights reserved.process is termed “concerted” as it leads to the coordinated
integration of both viral ends at the same host DNA site (Brown,
1997). DNA integration can be reconstituted in vitro. The in vitro assay
allows reproduction of the integration process as observed in vivo,
with cleavage of the two terminal nucleotides of the viral DNA ends
and the duplication of a short target DNA sequence. This assay has
been developed with INs from Avian Sarcoma and Leukemia Viruses
(ASLV) (Aiyar et al., 1996; Bera et al., 2005; Chiu and Grandgenett,
2000, 2003; Hindmarsh et al., 1999, 2001; Katz et al., 1990; McCord et
al., 1999; Moreau et al., 2003, 2004; Vora et al., 2004; Vora and
Grandgenett, 1995, 2001; Vora et al., 1994, 1997), Human Immuno-
deﬁciency type 1 (HIV-1), Simian Immunodeﬁciency Virus (SIV) and
Murine Leukemia Virus (MLV) (for review: Grandgenett et al., 2009;
Hindmarsh and Leis, 1999).
The viral DNA end sequences, termed IN recognition sequences or
att (attachment) sequences, correspond to imperfect inverted repeats.
The inverted repeat for ASLV contains 12 out of 15 terminal bp,
whereas that of HIV-1 contains 12 out of 20 terminal bp. The in vitro
assay generally uses a DNA substrate containing 20 bp for HIV-1 or
15 bp for ASLV derived from the ends of the terminal U3 and U5 IN
recognition sequences. By mutating speciﬁc nucleotides in the donor
DNA, this system has been used to evaluate the importance of the
95K. Moreau et al. / Virology 392 (2009) 94–102highly conserved CA dinucleotide (Aiyar et al., 1996) or nucleotides
at positions 3–11 of the ASLV and HIV-1 termini (Aiyar et al., 1996;
Brin and Leis, 2002a, 2002b; Chiu and Grandgenett, 2000; Vora et al.,
2004). Data show that nucleotides 5–7 from the ASLV U3 end
terminus signiﬁcantly affect integration (Chiu and Grandgenett, 2000;
Vora et al., 2004).
Early in vitro studies also explored the relationships between U3
and U5 IN recognition sequences by analyzing substrates thatFig. 1. Diagram of the in vitro concerted DNA integration assay and products. (A) Representa
gene (supF). U3–U5wild type substrate contains 15 bp of the U3 terminal viral sequence and 1
in Fig. 4). U3–ΔU5 is devoid of the viral U5 sequence; in pU3–U5, U3 is replaced by the pse
sequence and U3 is replaced by the pseudoU3 sequence. Substrates U3–U5, U3–ΔU5, pU
representation of the reconstituted integration reaction with the donor DNA, target plasmid
integration of both viral ends from a single donor (product a) and those that result from int
linear product b). Non-concerted integration products result from one-ended integration o
insertion at different sites on the target DNA (product d), and from one-ended integration of t
result from integration of donor DNA into a second donor DNA (product f). Adapted from Hcontained only one of these terminal recognition sequences either
for ASLV IN (Aiyar et al., 1996; Hindmarsh et al., 2001) or HIV-1 IN
(Brin and Leis, 2002a). Removal of one IN recognition sequence
resulted in a signiﬁcant loss of the entire integration products. For
instance, with HIV-1, the products decreased by 89% compared with
the wild type donor when the U5 recognition site was replaced by
random sequences, but this decrease was only by 10% when the U3 IN
recognition sequence was replaced. Concerted integration of HIV-1tion of the donor DNA substrates. Donor DNAs contain the amber mutation suppressor
2 bp of the U5 terminal viral sequence at ends (these IN recognition sequences are given
udoU3 sequences (see sequences in Fig. 4). The pU3–ΔU5 substrate is devoid of the U5
3–U5 and pU3–ΔU5 are 325, 249, 313 and 237 bp long, respectively. (B) Schematic
and puriﬁed IN protein. Concerted integration products include those that result from
egration of two viral ends from two donors at the same integration site (generating the
f a single donor DNA (product c), from two-ended integration of a single donor with
wo ormore donor DNAs at different sites on the target DNA (product e). Auto-integrants
indmarsh et al. (2001).
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Leis, 2002a). In contrast, the reduction was greater if the U3 IN
recognition sequence was replaced by random sequences than if U5
was mutated for the ASLV integration process (Aiyar et al., 1996).
In the present study, we used an in vitro assay that we previously
developed with the avian Rous Associated Virus type 1 (RAV-1) IN
protein (Moreau et al., 2003, 2004) to analyze the integration of DNA
substrates in which U3 or U5, or both sequences, were either replaced
by a mutated one (pseudoU3) or deleted (ΔU5), respectively. The
above-mentioned greater efﬁciency of integration when U5, rather
than U3, was substituted with random sequences, was corroborated.
Furthermore, by sequencing target plasmid–viral junctions, direct
evidence of authentic DNA integration was obtained with each of
these substrates, i.e. despite the absence of the two wild type IN
sequences, but the efﬁciency and accuracy (i.e. ﬁdelity of the
duplication size and of the cleavage ends) were reduced.
Results and discussion
Replacing U3 with pseudoU3 reduced the efﬁciency of integration at
least two fold whereas deleting U5 had only a slight effect on efﬁciency of
integration
The in vitro DNA integration assay used herein has already been
described (Moreau et al., 2003, 2004). The system consists of a linear
donor DNA (Fig. 1A), a 2.7 kb-long plasmid acceptor DNA and RAV-1
recombinant IN protein (Fig. 1B). The wild type (U3–U5) donor DNA is
325 bp long and carries the amber mutation suppressor gene (supF),
15 bp of the U3 viral terminal sequence and 12 bp of the U5 viral
terminal sequence at one and the other ends (Figs. 1A and 4 forFig. 2. Gel electrophoresis analysis of the integration products. Integration reactions performe
the U3–U5 (lane 2), U3–ΔU5 (lane 3), pU3–U5 (lane 4) and pU3–ΔU5 (lane 5) substrates in
visualized by autoradiography. The sizes of the lambda-Hind III marker fragments are indica
right. Structure of the recombinant accompanied by an ⁎ is unknown.nucleotide sequence of IN recognition sites). Three mutant donor
DNAs were also used (Figs. 1A and 4). In the U3–ΔU5 substrate
(249 bp long), the U5 IN recognition sequence was deleted (the
resulting non-viral sequence is thereafter named U5del). In the pU3–
U5 substrate (313 bp long), the U3 was replaced by a pseudoU3
sequence. The pseudoU3 matched the U3 terminus at 7 of the 15
bases. The end of pseudoU3matched thewt U3 at 5 of the 7 ﬁnal bases
(i.e. 5′ AAcGTtG compared to 5′ AATGTAG) (see Fig. 4). Thus, (i) the T
of the conserved TG dinucleotide (CA in the other strand) was
substituted by a C, (ii) the A in position 6 was substituted by a T, and
(iii) the conserved G in position 7 (Chiu and Grandgenett, 2000) was
not substituted. These U3 terminal base pairs contain the “bulk” of the
sequences needed for integration in the U3 end in vivo (Oh et al.,
2008b). Finally, in the pU3–ΔU5 substrate (237 bp long), the U3 IN
recognition sequence was replaced by the pseudoU3 sequence and U5
was deleted.
Reaction products with wt U3–U5 donor DNA, could arise by either
concerted or non-concerted integration involving one or both ends of
the donor DNA, as depicted in Fig. 1B (Aiyar et al., 1996; Hindmarsh
et al., 1999, 2001; Moreau et al., 2003, 2004). Concerted integration
products include those that result from integration of the two viral
ends from a single donor (product a) and those that result from
integration of two viral ends from two donors, at the same integration
site (generating the linear product b). Non-concerted integration
products result from one-ended integration of a single donor DNA
(product c), from two-ended integration of a single donor with
insertion at different sites on the target DNA (product d), and from
one-ended integration of two or more donor DNAs at different sites on
the target DNA (product e). Auto-integrants result from integration of
donor DNA into a second donor DNA (product f). Thus, products a andd with the radiolabeled U3–U5wild type substrate in the absence of IN (lane 1), or with
the presence of IN. DNA integration products were separated on a 1.2% agarose gel and
ted on the left side of the picture. Schematized integration products are shown on the
Table 1
Efﬁciency of integration of the various donor DNAs.
Donor DNA
U3–U5 U3–ΔU5 pU3–U5 pU3–ΔU5
Efﬁciency of integrationa 100.0 97.8 44.7 42.5
Efﬁciency of two-ended integration (%)b 100.0⁎ 42.0⁎ 27.7⁎ 21.1⁎
Efﬁciency of concerted integration (%)c 100.0 80.0 88.4 39.2⁎
Efﬁciency of two-ended and
concerted integrationd
100.0 33.6 24.5 8.3
a Efﬁciency of integration as deduced from gels (Fig. 2), which takes into account one-
ended and two-ended integration products (RFII+RFIII forms on Fig. 2). Results are the
mean of at least three independent experiments.
b Efﬁciency of two-ended DNA integration (considering products resulting from
concerted integration (a) and non-concerted integration (d) as revealed by cloning on
bacteria) in comparison to the U3–U5 wild type substrate that was set at 100%. Results
are the mean of at least three experiments.
c Efﬁciency of concerted integration in comparison with the wt DNA that was set at
100% (data from Table 2).
d Efﬁciency of two-ended and concerted integration is efﬁciency of two-ended
integration×efﬁciency of concerted integration×100.
In (b) and (c): ⁎The difference between themarked values substrate and each other value
is signiﬁcant (Fisher's test; pb0.05).
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concerted integration and of a two-ended and non-concerted
integration, respectively.
Integration of the donor DNA into the larger target DNA could be
visualized by using labeled donor DNA and autoradiography after
separation on agarose gel. The experiment was repeated at least three
times. A representative experiment is shown in Fig. 2. No bands other
than the labeled donor DNA were revealed when IN was omitted from
the reaction (Fig. 2, lane 1). Three characteristic sets of bands were
revealed in the presence of IN (lane 2): the slowest set of bands
corresponds to amixof circular forms (Recombinant FormRFII products:
a, c, d and e), the middle set of bands corresponds to linear form b (RFIII
product) and the fastest set of bands corresponds to auto-integration
products (form f) (Moreau et al., 2003, 2004). The percentage of wt
donor substrate incorporated into RFII and RFIII products was 4.7%.
All three characteristic sets of bandswere revealed on gel when the
U3–ΔU5, pU3–U5 and pU3–ΔU5 substrates were used (Fig. 2, lanes 3,
4 and 5). The efﬁciency of generation of integration products was
greatly decreased when the donor DNAs carried the pseudoU3 either
in the presence of the U5 sequence (compare wt U3–U5 and pU3–U5
substrates (lanes 2 and 4)) or in the presence of the U5del sequence
(compare U3–ΔU5 and pU3–ΔU5 (lanes 3 and 5)). The proportions of
pU3–U5 and pU3–ΔU5 donor substrates incorporated into RFII and
RFIII products were 2.1% and 2.0%, corresponding to 44.7% and 42.5%
of the wt U3–U5 (set at 100%), respectively (Table 1). Thus, one of the
consequences of replacing U3with pseudoU3was to reduce by at least
two fold the efﬁciency of the entire integration process (indepen-
dently of the sequence at the U5 position (U5 end or not)). In contrast,
the integration of donor DNAs containing a wild type U3 and no U5 IN
recognition sequence (U3–ΔU5) produced high levels of integration
products (4.6% of U3–ΔU5 donor substrate was incorporated into RFII
and RFIII products; Fig. 2, lane 3). This corresponds to 97.8% of the wt
U3–U5 (set at 100%) (Table 1). Thus, comparison of the efﬁciencies of
integration of U3–U5 with U3–ΔU5 (100.0 and 97.8%) and pU3–U5
with pU3–ΔU5 (44.7 and 42.5) (Table 1) revealed that, in the presence
of a wt U3 or a pseudoU3 sequence, the deletion of U5 sequences had
only a slight effect on the whole integration process. These data
corroborated those reported by other authors (Aiyar et al., 1996;
Hindmarsh et al., 2001) who showed that the ASLV U3 IN recognition
sequence provided a more efﬁcient substrate than U5 for integration.
IN is able to catalyze concerted integration of the two ends of substrates
carrying either the pseudoU3 sequence or a non-viral sequence (U5del),
or both
The integration products observed with the double mutant
(devoid of both wt IN recognition sequences on the two ends
(pU3–ΔU5)) were not expected. We therefore checked that IN was
indeed able to integrate the pseudoU3 sequence or the non-viral
U5del ends into target DNA. To distinguish each end separately, we
performed an in vitro integration assay using donor DNAs labeled at
one end only (rather than all along the substrate as in Fig. 2), as
exempliﬁed with the U3–ΔU5 donor DNA in Fig. 3A. Radiolabeled
donor DNAs were incubated with target DNA and IN under the
integration reaction conditions. The reaction products were then
digestedwith BamHI restriction enzymewhich cleaves once inside the
donor DNA. The BamHI digestion removed that part of the donor DNA
which was not joined to target plasmid DNA. Consequently, only the
products that were integrated by the pseudo or non-viral end-labeled
sequence should be detected after gel autoradiography, whereas
products resulting from use of the viral IN recognition sequence
should not be observed. In addition, the BamHI digestion helps to
separate the non-concerted integration products (c, d and e which
remain circular) from the concerted products (awhich becomes linear
and b that remains linear). As the BamHI restriction site is present at
one extremity of the donor DNA, fragments with different sizes shouldbe observed depending on how the donor DNA ends were integrated
into the target plasmid (Fig. 3B, top). Wild type donor DNA, labeled at
its U5 and that labeled at its U3 viral ends were used as a controls
(Fig. 3B, columns 1 and 3, lanes 1–2 and 5–6). On completion of the
integration reaction, high molecular weight products were observed
in two sets of bands corresponding to the RFII and RFIII bands of Fig. 2
(Fig. 3B, lanes 1 and 5). After BamHI digestion, high molecular weight
products were also observed in twomain sets of bands (lanes 2 and 6).
The upper set of bands corresponded to circular integration products
(c, d and e), resulting from non-concerted events, while the lower set
of bands (3290 and 3017 bp in lane 2, 3017 and 2774 in lane 6)
corresponded to the linear forms of integration products (a and b)
resulting from concerted DNA integration.
The U3–ΔU5 and pU3–U5 donor DNAs were then labeled at their
pseudoU3 or U5del ends (Fig. 3B, columns 2 and 4, lanes 3–4 and 7–8)
and the pU3–ΔU5 donor DNA was labeled at either one or other end
(columns 5 and 6, lanes 9–10 and 11–12). Labeled donor DNAs were
then used as IN substrates in the integration assay. With all substrates,
two sets of bands of high molecular weight were revealed by
autoradiography, corresponding to integration of the donor DNA
into target plasmid DNA (Fig. 3B, lanes 3, 7, 9 and 11). This indicated
that all substrates were used in the integration reactions. After BamHI
digestion, two slightly smaller sets of bands were revealed (Fig. 3B,
lanes 4, 8, 10 and 12), corresponding in size to the products expected
from concerted DNA integrations (columns 2, 4, 5 and 6).
Altogether, these data demonstrated that pseudoU3 sequences of
the pU3–U5 and pU3–ΔU5 substrates as well as the U5del sequence at
the U5 end of the U3–ΔU5 and pU3–ΔU5 substrates were recognized
and used by IN in the integration reactions. Furthermore, we showed
that the products formed by IN were the results of both concerted and
non-concerted integrations.
Replacing U3 with pseudoU3 or deleting U5 reduced the two-ended
integration three and two fold, respectively
We then focused on the ability of IN to perform two-ended DNA
integration (concerted (product a) and non-concerted (product d))
with the different DNA donor substrates (Fig.1B). Integration products
(from the whole integration reaction mixture) were cloned into
MC1061/P3 Escherichia coli bacteria. We used this bacteria strain
because it contains drug resistant markers with amber mutations.
Only DNA products carrying the supF gene (amber mutation
suppressor gene) should be able to replicate and form colonies
under drug selection. In addition, among the different integration
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Fig. 4. Sequencing of cleavage sites in the donor DNAs. The U3, pseudoU3, U5 or U5del ends of each donor DNA are represented. The two nucleotides processed during normal
integration are indicated in italics. Arrows show the sites of cleavage and integration and the numbers indicate the number of clones found to be integrated at each position.
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products (forms a (concerted) and d (non-concerted) should be able
to replicate in the bacteria. The efﬁciency of the two-ended integration
process (both non-concerted and concerted) can thus be estimated by
cloning into these bacteria. For each DNA substrate, cloning efﬁciency
was determined from the number of clones obtained in relation to the
number of clones obtained with the wild type donor DNA. As
previously observed (Moreau et al., 2004), no bacterial clone was
obtained in the absence of IN. The proportions of two-ended
integration of the U3–ΔU5, pU3–U5 and pU3–ΔU5 donor DNAs, in
comparison to the wild type donor (set at 100%), were 42.0%, 27.7%
and 21.1%, respectively (Table 1). The differences in clones number
between each substrate and another is signiﬁcant (Fisher's test;
pb0.05).
Molecular characterization of integration products revealed that
replacing U3 with pseudoU3 or deleting U5 did not highly affect
concerted integration
Following cloning, the donor DNA–acceptor plasmid junctions of
isolated integration products were sequenced to discriminate
between concerted (form a) and non-concerted (form d) integration
products (Brin and Leis, 2002a, 2002b; Moreau et al., 2003, 2004).
With the U3–U5 wild type substrate, twenty-eight clones were
ampliﬁed and sequenced at the donor–target DNA junctions (resultsFig. 3. Test of the ability of IN to integrate substrates with pseudo or non-viral DNA end(s).
substrate. The donor DNA was labeled at its non-viral end only (⁎) and the integration react
resulting from the integration of one or more donor DNA ends, are indicated. For example,
molecules. For each product, the position of the BamHI restriction site, which cleaves once in
Digestion of integration products by BamHI removed the end of the donor DNA which was n
radiolabeled non-viral end of the donor DNA could be visualized on gel. Target DNAs which
with the U3–U5, U3–ΔU5, pU3–U5 and pU3–ΔU5 substrates labeled at only one end. Top:
digestion are given. Bottom:Gel analysis of integrationproducts. Integration reactionswere pe
with theU3–ΔU5 substrate labeled at the delU5 end (column 2, lanes 3–4), with theU3–U5w
labeled at the pseudoU3 end (column 4, lanes 7–8), andwith the pU3–ΔU5 substrate labeled
Gel electrophoresiswas carried out as in Fig. 2. Productswere either not digested (ND: lanes 1,
digestion products (i.e. products resulting from concerted integration events) are indicated
efﬁciency of labeling was very different for each DNA substrate; hence, the intensities of thedepicted in Fig. 4, Supplemental materials-A, and Table 2). Fourteen
clones exhibited a duplication of 6 bp of target DNA and eleven clones
a duplication of other size (from 5 to 7 bp) (Table 2). In vivo, the 6 bp
duplication has been shown to be a hallmark of ASLV viruses (Hughes
et al., 1981; Ju et al., 1980), although some size variations (Moreau
et al., 2000) and longer duplications in experimental systems
(Oh et al., 2006a, 2006b, 2008a) have been reported. Shorter and
longer duplications are frequently observed in vitro (Aiyar et al., 1996;
Hindmarsh et al., 1999, 2001; Moreau et al., 2003, 2004). Three clones
(of type d) (Supplemental materials-A, clones 56, 57 and 348),
exhibited a deletion of target DNA at the integration sites varying from
255 to 888 bp in size. However, as these clones were correctly cleaved
at both ends and integrated between the canonical TG and CA viral
dinucleotides they were interpreted as being the result of an IN-
mediated process but with incorrect cleavage of the target DNA. Thus,
most of the two-ended integration products obtained with U3–U5
wild type donor DNA and ampliﬁed in bacteria (25/28 i.e. 89.3%)
(Table 2) resulted from a two-ended and concerted DNA integration
event in our experimental system. This rate is similar to those we
previously reported that ranged from 87 to 95% (Moreau et al., 2003,
2004). Regarding the donor DNA ends (Fig. 4), most of the clones
showed deletion of two nucleotides and presented the characteristic
5′-TG and CA-3′ viral ends. More than the two expected nucleotides
were deleted from the U3 or U5 sequences in some cases (six in U3
and one in U5) (Fig. 4 and Supplemental materials-A, clones 13, 199,(A) Principle of the test. Principle is explained with the example of the U3–ΔU5 donor
ion was conducted as in Fig. 2. All theoretical integration products of type a, b, c d or e,
three different b products are expected depending on the orientation of the integrated
side the donor and does not cleave inside the target DNA, is schematized by a small line.
ot joined to target plasmid DNA. This meant that only target DNA which integrated the
could not be visualized are shown in grey. (B) Analysis of integration products obtained
For each end-labeled donor DNA, the type and size of expected products after BamHI
rformedwith theU3–U5wild type substrate labeled at theU5 end (column1, lanes 1–2),
ild type substrate labeled at the U3 end (column3, lanes 5–6), with the pU3–U5 substrate
at either the pseudoU3 (column 5, lanes 9–10) or the U5del end (column 6, lanes 11–12).
3, 5, 7, 9 and 11) orwere digestedwith BamHI (B: lanes 2, 4, 6, 8,10 and 12). Linear BamHI
by a dot. Next to the picture are the sizes of the integration products. [Note that the
integration products cannot be compared with each other].
Table 2
Sequencing of donor–target junctions from clones obtained with the different donor
DNAs.
Target DNA at the integration site Donor DNA
U3–U5 U3–ΔU5 pU3–U5 pU3–ΔU5
Duplication of 6 bpa 14 8 4 1
Other size of duplicationb 11 7 11 6c
Deletiond 3 6 4 13
Total number of clones 28 21 19 20
Percent of clones that are concertede 89.3 71.4 78.9 35.0
a After cloning integration reaction products into MC1061/P3 E. coli bacteria, several
integration products were ampliﬁed and sequenced for each substrate. Both donor–
target DNA junctions were sequenced. The duplication of a short sequence of target DNA
is themark of a two-ended and concerted DNA integration process (generating clones of
type a) whereas a deletion of target DNA is the mark of a two-ended and non-concerted
DNA integration process (generating clones of type d).
b From 4 to 7 bp.
c Among these clones, one with a 5 pb duplication also displayed the insertion of 5 nt
of unknown origin (clone 57, Supplementary materials-4).
d Deletions range from 255 to 888 bp, 106 to 898 bp, 2 to 1113 bp and 22 to 760 bp for
U3–U5, U3–ΔU5, pU3–U5 and pU3–ΔU5 donor substrates, respectively.
e Number of clones with a duplication of target sequences divided by total number of
clones×100.
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acceptor DNA at the integration site, we concluded that they indeed
arose from an IN-mediated integration process, but with incorrect
cleavage of the terminal sequences. We are conﬁdent that the clones
analyzed by sequencing were the result of IN activity rather than
recombination in bacteria for the following reasons: (i) no colony was
recovered when reactions performed with target and donor DNAs in
the absence of IN were subjected to cloning analysis; (ii) products
displaying duplication of target DNA (type a) were clearly the result of
an IN-mediated process; and (iii) the type d products showing a
deletion of target DNA and cleavage of a few nucleotides at the DNA
terminus (2 nucleotides in most cases) were already observed with
the wild type substrates (Moreau et al., 2003, 2004) as well as
reported by other authors (Sinha et al., 2002; Vora et al., 1997) and
were attributed to the action of IN.
For the U3–ΔU5 substrate, twenty-one clones were sequenced
(Table 2). Eight clones displayed a duplication of 6 bp and seven
clones a duplication of other size (4–5 bp). Six clones displayed a
deletion of target DNA ranging from 106 to 898 bp in size. Thus, ﬁfteen
clones out of twenty-one (71.4%) had the proﬁle of two-ended and
concerted DNA integration (Table 2). This efﬁciency corresponded to
80.0% of that of the wild type donor (set as 100%) (Table 1). Regarding
the donor DNA ends (Fig. 4, Supplemental materials-B), all clones
were correctly deleted of two nucleotides at the U3 viral end and
presented the characteristic 5′ TG end. It is noteworthy that the same
end of the wild type donor was not cleaved with such ﬁdelity in all
clones. We are not able to explain this observation at present. One
clone was deleted of 1 bp at the non-viral end, (Supplemental
materials-B, clone 64). The twenty other clones derived from U3–ΔU5
were not processed at the U5del end and were all integrated at the
terminal CG dinucleotide (Fig. 4 and Supplemental materials-B).
For the pU3–U5 substrate, nineteen clones were sequenced at the
donor–target DNAs junctions (Table 2 and Fig. 4). Fifteen clones
displayed duplication of a short target DNA sequence of the expected
6 bp (four clones) or of other size (3–7 bp) (eleven clones), on each
side of the integrated donor. Four clones displayed a deletion of target
DNA ranging from 2 to 1113 bp in size (Table 2). Thus, 15 out of 19
clones (i.e. 78.9%) resulted from a two-ended and concerted DNA
integration event (Table 2). This efﬁciency corresponded to 88.4% that
of the wild type donor (set as 100%) (Table 1). Regarding the U5 viral
end (Fig. 4), all nineteen clones were correctly deleted of two
nucleotides of donor DNA and the viral DNAs were ﬂanked by the
characteristic CA 3′-end. Regarding the non-viral end, sixteen clones
were processed of two nucleotides as expected. However, thiscleavage involved a CG dinucleotide rather than the CA dinucleotide.
As a result, these clones were not ﬂanked by the canonical 5′ TG but by
a CG dinucleotide. In the last three clones, deletions of 1 bp, 4 bp and
5 bp of donor DNA end sequences were observed (Fig. 4, clones 4, 49
and 74, Supplementary materials-C). The clone, which was deleted of
5 bp, was cleaved at an internal CA at the pseudoU3 end (Fig. 4).
Altogether, these data showed that replacing U3 with pseudoU3 or
deleting U5 did not highly affect concerted integration.
Replacing U3 by pseudoU3 and deleting U5 increased the non-concerted
integration events which were favored over the concerted ones
Twenty bacteria clones selected randomly were used to examine
the pU3–ΔU5 substrate which contained a pseudoU3 sequence and no
viral sequence at the other end (Table 2). Seven clones (35.0%)
displayed a duplication of the target DNA sequence on each side of the
integrated DNA andwere interpreted as resulting from two-ended and
concerted DNA integration events (clones 3, 33, 39, 60.2, 64 and 67,
Supplemental materials-D). Only one displayed the characteristic
duplication of 6 bp. One clone with a 5 bp duplication displayed an
insertion of 5 bp at the integration site (clone 57, Supplemental
materials-D). These 5 bp did not correspond to either the donor DNA
end sequences or to the integration site sequences and remained from
unknown origin. This clone was interpreted as being the result of an
integration event since it was ﬂanked by a duplication of the target
DNA sequence (see Supplemental materials-4, clone 57). Thirteen
clones displayed a deletion of target DNA at the integration site ranging
in size from 22 to 760 bp. Compared to other substrates, the proportion
of two-ended and concerted DNA integration generated with the
pU3–ΔU5 substrate is low (35.0% of clones (7/20) Table 2). [This
efﬁciency corresponds to 39.2% that of the wild type donor set as 100%
(Table 1).] This difference between pU3–ΔU5 and each other substrate
is signiﬁcant (Fisher test; pb0.05). Thus, the absence of both wt IN
recognition sequences resulted in a change in the proportion of non-
concerted integration events which were favored over the concerted
integration events. With respect to the ends of the integrated
molecules (Fig. 4), most of the clones (17/20) were deleted of two
nucleotides at the pseudoU3 end despite the absence of the canonical
TG dinucleotide (Fig. 4). As observed at the pseudoU3 end of the pU3–
U5 substrate, the cleavage involved a CGdinucleotide in place of the CA
dinucleotide. Two clones were deleted of 4 and 5 nucleotides and the
last clone had not been processed at the end (Fig. 4, clone 58 in
Supplementalmaterials-D). Regarding the end at U5 position,19 out of
20 clones were not processed andwere integrated as such at non-viral
termini of the U3–ΔU5 substrate. A single base was processed in one
clone. It should be noted that the clone not processed at the pseudoU3
endwas not processed at the U5del either (clone 58 in Supplementary
materials-D). This suggests that the integration of a substrate
uncleaved at both ends is possible, but occurs rarely.
U3 IN recognition sequence is dominant over the U5 IN recognition
sequence for two-ended integration, but both are equivalent for
concerted integration
As mentioned above, one consequence of replacing U3 by the
pseudoU3 sequence is to reduce the efﬁciency of global integration at
least two fold (Fig. 2 and Table 1). However, the main consequence of
replacing U3 by the pseudoU3 in the presence of a wild type U5
sequence, is to reduce the two-ended integration frequencymore than
3 fold (27.7% that of the wild type), without highly affecting the
concerted integration (88.4% that of the wild type substrate). Other
authors (Vora et al., 2004) showed that nucleotides 5, 6 and 7
signiﬁcantly affected the concerted integration (calculated by mea-
suring the RFIII linear product b) and that sequences at position 9–11
also partially decreased the ability of IN to promote concerted
integration (50%). In contrast, sequences after the 11th nucleotide
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et al., 2004). Therefore, the effect of reducing two-ended integration
in our model may be mainly due to replacement of nucleotides 6 (and
maybe 8) as well as of nucleotides 10 and 11.
Similarly, the absence of U5 sequences in the extremity (and,
hence the absence of cleavage of this end) did not impair the global
integration observed on gel (see above and Fig. 2 and Table 1). Further,
the absence of U5 end did not strongly impair the concerted
integration process, at least in the presence of a wild type U3 (80.0%
that of the wild type substrate) (Table 1). Conversely, the main effect
of deleting U5, in the context of U3, was to reduce the efﬁciency of
two-ended integration more than twofold (42.0% that of the wild type
substrate).
Therefore, our data not only corroborate other data showing that
the ASLV U3 IN recognition sequence is dominant over the U5 IN
recognition sequence for integration (Aiyar et al., 1996; Hindmarsh
et al., 2001) but also they demonstrated that the U3 IN recognition
sequence is dominant over the U5 IN recognition sequence for two-
ended integration. In contrast, deleting U5 or replacing U3 by a
pseudoU3 did not result in marked effects on the efﬁciencies of
concerted integration (Table 1).
Finally, the two-ended integration efﬁciencies estimated by
cloning on bacteria and the percentage of concerted integration
products revealed by sequences of clones were taken into account to
determine the efﬁciency with which IN speciﬁcally performed DNA
integrations that are two-ended and concerted with the different
substrates. These efﬁciencies were 33.6%, 24.6% and 8.3% that of thewt
U3–U5 donor with the U3–ΔU5, pU3–U5 and pU3–ΔU5 donor
substrates, respectively (Table 1).
Cleavage of two nucleotides at the U3 end, but not at the U5 end, is
important for proper integration
As observed in Fig. 4, the U3 and pseudoU3 sequences were
reproducibly cleaved in all clones except one. Even in the absence of
the canonical CA, two nucleotides were most often deleted and
integration by the pseudoU3 occurred at a CG dinucleotide (Fig. 4).
Mutated U3 viral ends were also frequently deleted of two base pairs
in other in vitro studies (Aiyar et al., 1996; Hindmarsh et al., 2001)
and the ASLV CA dinucleotide was shown to be not essential for
specifying the cleavage site (Katz et al., 2001). In vivo, RSV IN can
successfully remove two nucleotides beyond a mutated sequence
(which replaces the canonical CA) in the U3 IN recognition sequence,
and was able to integrate properly with a 5/6 bp duplication of
target sequences (Oh et al., 2008a, 2008b). Altogether, these data
suggested that while cleavage of two nucleotides in the U3 end
seems to be important for appropriate integration, the cleavage at
the CA dinucleotide is not required at the U3 end neither in vitro nor
in vivo (Oh et al., 2008a, 2008b).
Cleavage of the U5del end was not found to be an absolute
prerequisite for two-ended integration sincemost clones derived from
U3–ΔU5 and pU3–ΔU5 were not processed at the U5del end and,
hence, were integrated at the terminal CG dinucleotide. In that cases,
integration of substrates with the uncleaved end at the U5 position
successfully generated 4 to 7 bp duplication of target DNA (Table 2)
which is the mark of an integration performed by IN. Thus, even in the
absence of cleavage of this end, the ASLV IN remains able to integrate
both ends in a two-ended and concerted integration. Integrations of
unprocessed U5 junctions were also described using Rous Sarcoma
Virus (RSV) (Oh et al., 2006b). However, our results differ from those
in vivo, where the aberrant U5 end was found to be integrated by
unusual processes creating deletion or large duplications which were
interpreted as resulting from the action of cellular enzyme instead of
the action of IN (Oh et al., 2006b).
Our data raise the issue of how IN recognizes the U5del non-viral
end. It was previously shown that ASLV IN is able to bind heterologousHIV IN recognition sequences (that differ in sequence from ASLV DNA
sequences in most positions) (Katz et al., 2001). Thus, one possibility
is that the DNA end itself plays a role in recognition, in a sequence-
independent manner. After binding of the viral end, disruption of
terminal bases pairs is a required step for 3′-processing (Katz et al.,
2001; Scottoline et al., 1997). This end processing by IN requires IN
recognition sequences (Scottoline et al., 1997). Altogether, these data
and ours suggest that deletion of the IN recognition sequence does not
abolish IN binding to DNA ends but abolishes processing of this non-
viral end.
The results in vitro also conﬁrm that in the active ASLV IN
complex, the cleavage of the U3 end can be performed indepen-
dently of the U5 end, since clones not cleaved at the U5 end were
correctly cleaved at the U3 or pseudoU3 most of the times. It was
shown in vivo, that RSV IN can process the normal U3 end,
independently of the U5 end and vice versa (Oh et al., 2006a,
2006b, 2008a, 2008b). This property of ASLV IN is shared with HIV
IN for which many studies have demonstrated that two functional
viral ends are not necessary for HIV IN 3′ processing activity in vivo
(Chen and Engelman, 2001; Masuda et al., 1998). In contrast, with
MLV, a pair of functional viral ends had to interact before IN could
be activated to cleave either end (Murphy and Goff, 1992; Wei et al.,
1998).
Conclusion
We have shown in the in vitro assay, that the ASLV IN complex
was able to carry out the two-ended and concerted integration of a
substrate either carrying a mutated U3 sequence (pseudoU3) or
deleted of U5 sequences, or carrying both modiﬁcations, albeit with
reduced efﬁciency and accuracy. This suggests that, even in the
absence of the two wild type IN recognition sequences, IN remains
able to associate in a complex competent for integration (probably
a dimer for cleavage and a tetramer for two-ended and concerted
DNA integration (Faure et al., 2005; Guiot et al., 2006)).
Furthermore, the data strongly suggest that the cleavage of the
U5 end of the donor DNA is not an absolute prerequisite for two-
ended integration (concerted or not), whereas cleavage of the U3
end is required. The need to process only one end is shared by the
ASLV IN and spumaretroviruses IN. Indeed, during integration of
foamy virus, the U5 end of the cDNA is processed, whereas the
downstream (U3) remains uncleaved and the canonical TG motif at
the beginning of the provirus is not essential for foamy virus
integration (Juretzek et al., 2004). Neither end is cleaved during Ty1
retrotransposition (Mules et al., 1998). We therefore speculate that
ASLV IN has conserved an ancient ability shared by other retro-
viruses or retrotranspons to integrate a substrate without cleavage
of both ends.
Materials and methods
Donor DNAs
The donor DNAs used in the present study were ampliﬁed from the
BSK-supF plasmid (Moreau et al., 2004) with the following primers:
U3 bis (AATGTAGTCTTATACGTTGCCCGGATCCGG 3′) (BamHI site is
underlined) and U5 bis (5′ AATGAAGCCTTCTGCTTTGAGCGTC-
GATTTTTG 3′) primers for wild type U3–U5 donor DNA, U3 bis and
SUP3 (5′ CGCCGAATTCTTTCTCAACG 3′) primers for U3–ΔU5 donor
DNA, SUP1 (5′ AACGTTGCCCGGATCCGGTC 3′) (BamHI site is under-
lined) and U5 bis primers for pU3–U5 donor DNA, and SUP1 and SUP3
primers for pU3–ΔU5 donor DNA. The PCR products were puriﬁed
from agarose gel using the Qiaex II kit (Qiagen). The high-ﬁdelity pfu
turbo DNA polymerase that generates blunt-ended PCR products
(Promega) was used.
102 K. Moreau et al. / Virology 392 (2009) 94–102Labeling donor DNA
For gel analysis of integration products (Fig. 2), donor DNAs were
labeled all along the molecule by including 8 μCi of dCTPα32P in the
PCR ampliﬁcation mixture. When only one end of the donor DNA had
to be labeled (Fig. 3), primers were ﬁrstly 5′-end labeled before being
used for PCR ampliﬁcation. For this purpose, 10 pmol of oligonucleo-
tides was 5′-end labeled with 10 units of T4 polynucleotide kinase
(Ozyme) as described by the supplier and in the presence of 50 μCi of
γ-32P ATP.
Other experiments
All other experiments (puriﬁcation of proteins, integration reac-
tion [except that HMGI was omitted in the present study], gel analysis
of the integration reaction, cloning and sequencing of the two-ended
integration products) were conducted as previously described
(Moreau et al., 2002, 2003, 2004). The target DNA (BSK-Δ2-zeo)
was 2692 bp long.
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